Hodgkin Lymphoma Research Review, Issue 9

In this issue:

KEYNOTE-204: Pembrolizumab extends PFS compared to BV in relapsed disease
Is chemotherapy or transplant a better first salvage therapy for early-stage, favourable disease?
Dose-intensified chemotherapy confers long-term disease control in unfavourable early-stage HL
BV in combination with nivolumab in relapsed or refractory disease
Subsequent malignant neoplasm risk highest among children with HL who receive radiotherapy
Front-line pembrolizumab plus chemotherapy shows promise for newly diagnosed, unfavourable HL
Transplant after anti-PD-1 therapy for multiply relapsed or refractory HL
EFS status after transplant prognostic for survival in lymphoma
NHL after treatment for classical HL is rare but has a high mortality rate
BREVITY finds BV for patients unsuitable for chemotherapy suboptimal in front-line setting

Please login below to download this issue (PDF)

Subscribe